Reading view
Unveiling the Diagnostic Value and Potential Therapeutic Targets of Phenylalanine Metabolism in Pancreatic Cancer via Integrated Multi-Omics and Machine Learning
FASEB J. 2026 Sep 30;40(18):e72296. doi: 10.1096/fj.202603069R.
ABSTRACT
Pancreatic cancer (PC) presents a significant global health challenge because of its high mortality rate, highlighting the urgent requirement for effective early diagnostic and therapeutic strategies. This study examined the function of phenylalanine metabolism in PC and developed a high-accuracy diagnostic model by integrating metabolomics, Mendelian randomization (MR), and machine learning (ML) algorithms. Initially, MR analysis was conducted on 55 plasma metabolites, revealing a significant causal link between phenylalanine and PC. Utilizing GeneCards and public transcriptomic databases, we determined eight differentially expressed genes (DEGs) in PC associated with phenylalanine. Based on these genes, we utilized 12 ML algorithms, totaling 113 combinations, to select the optimal diagnostic model. We applied Shapley Additive exPlanations (SHAP) for feature interpretation and constructed a prognostic nomogram with strong predictive performance by incorporating clinical variables. Furthermore, immune infiltration analysis demonstrated strong connections between these key genes and specific immune cell populations. Based on the SHAP value, we conducted single-cell RNA sequencing (scRNA-seq) data and simulated gene knockout analyses using SLC6A14 as the key gene. Drug target prediction-guided molecular docking and molecular dynamics simulations, focusing on the core gene SLC6A14, confirmed the high binding stability of candidate compounds. Finally, in vitro cell experiments quantitative real-time PCR (RT-qPCR) verified the expression trends of the key genes in PC cell lines. In conclusion, this study successfully developed an ML diagnostic model with high biological interpretability. This analysis aims to identify biomarkers related to phenylalanine metabolism and potential therapeutic drugs for PC, offering new strategies for personalized targeted therapy of PC.
PMID:42730913 | PMC:PMC13570651 | DOI:10.1096/fj.202603069R
Artificial intelligence-assisted early screening of lung cancer and accurate diagnosis of pulmonary nodules: research progress and clinical prospects from radiomics to multi-omics integration: a narrative review
J Thorac Dis. 2026 May 31;18(5):537. doi: 10.21037/jtd-2026-1-0315. Epub 2026 Apr 30.
ABSTRACT
BACKGROUND AND OBJECTIVE: Lung cancer remains one of the leading causes of cancer-related death worldwide. Although low-dose computed tomography (LDCT) has improved early detection, false-positive results, overdiagnosis, and interobserver variability continue to limit screening efficiency and downstream management of pulmonary nodules. This narrative review summarizes recent progress in artificial intelligence (AI)-assisted screening, radiomics-based nodule characterization, and multi-omics integration for the precision diagnosis of lung cancer.
METHODS: A narrative review with thematic analysis was conducted using representative literature on AI-assisted lung cancer screening, quantitative imaging analysis of pulmonary nodules, radiogenomic and multi-omics integration, and clinical translation challenges. Studies were synthesized to highlight technical advances, diagnostic performance, strengths, limitations, and barriers to implementation.
KEY CONTENT AND FINDINGS: AI improves nodule detection, second-reader support, workflow efficiency, and malignancy-risk estimation in LDCT screening. Radiomics converts CT images into quantitative features that can improve discrimination between benign and malignant nodules, especially when combined with clinical variables or deep-learning models. Beyond imaging alone, radiogenomic and other multi-omics approaches link imaging phenotypes with molecular alterations, treatment response, and prognosis, thereby supporting more individualized management. However, current evidence remains limited by dataset heterogeneity, retrospective design, limited interpretability, and insufficient multicenter prospective validation.
CONCLUSIONS: AI-based imaging and multi-omics integration offer a promising pathway toward earlier detection and more precise diagnosis of lung cancer. Broader clinical adoption will depend on standardized data acquisition, robust external validation, interpretable models, and careful governance of privacy, ethics, and workflow integration.
PMID:42306713 | PMC:PMC13266817 | DOI:10.21037/jtd-2026-1-0315
Non-enzymatic function of QSOX2 directly regulates the JUNB-ITGB4 axis and enhanced resistance to osimertinib in EGFR-mutation lung adenocarcinoma
Cell Death Discovery, Published online: 01 April 2026; doi:10.1038/s41420-026-02969-4
Non-enzymatic function of QSOX2 directly regulates the JUNB-ITGB4 axis and enhanced resistance to osimertinib in EGFR-mutation lung adenocarcinoma